




RealRate

PHARMACEUTICAL 2020

AMAG PHARMACEUTICALS INC.
Rank 222 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

AMAG PHARMACEUTICALS INC. Rank 222 of 362

The relative strengths and weaknesses of AMAG PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AMAG PHARMACEUTICALS INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 183% points. The greatest weakness of AMAG PHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 142% points.

The company's Economic Capital Ratio, given in the ranking table, is -243%, being 59% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	316,567
Cost of Goods Sold	107,193
Intangible Assets	446,133
Liabilities, Current	208,194
Liabilities, Non-Current	19,880
Other Assets	24,411
Other Compr. Net Income	746
Other Expenses	314,565
Other Liabilities	277,034
Other Net Income	-20,996
Property and Equipment	4,116
Research and Development	64,853
Revenues	327,751
Selling, General and Administrative Expense	286,600

Output Variable	Value in 1000 USD
Assets	791,227
Liabilities	505,108
Expenses	773,211
Stockholders Equity	286,119
Net Income	-466,456
Comprehensive Net Income	-466,083
Economic Capital Ratio	-243%

